During Thursday’s Current trade, Shares of Manulife Financial Corporation (USA)(NYSE:MFC), lost -1.17% to $15.14.
Manulife Investments, a division of Manulife Asset Administration Limited (MAML), recently declared a number of projected changes to its mutual fund lineup. The changes follow the acquisition of the Canadian-based operations of Standard Life plc accomplished earlier this year and are part of the ongoing integration of the Standard Life Mutual Funds into the Manulife fund family. Subject to applicable regulatory and securityholder approval, Manulife Investments proposes to:
- amalgamate the existing Standard Life and Manulife mutual fund corporations.
- change the investment objectives of certain funds.
- change the sub-advisors and portfolio managers of certain funds.
- cap certain funds to new purchases.
- implement a series of fund mergers.
In an effort to create a stronger mutual fund corporation and to allow for tax-deferred switching between the Standard Life corporate funds and the Manulife corporate funds, in addition to tax-deferred mergers between these funds, Manulife Investments is proposing to amalgamate Standard Life Corporate Class Inc. (“SLCCI”) and Manulife Investment Exchange Funds Corp., on a tax-deferred basis, into a single corporate entity (the “Corporate Amalgamation”).
Manulife Financial Corporation, together with its auxiliaries, provides financial protection and wealth administration products and services to individual, corporate, and business customers primarily in Asia, Canada, and the United States.
Shares of AstraZeneca plc (ADR)(NYSE:AZN), declined -0.31% to $32.20, during its current trading session.
Allergan plc (AGN) declared that its infectious disease portfolio will be featured in 24 abstracts highlighting new data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015, which takes place from September 17-21, 2015 in San Diego.
Allergan will present data from studies further evaluating: the antimicrobial activity against certain gram negative isolates and pharmacokinetics of AVYCAZ™ (ceftazidime-avibactam); in-vitro activity and susceptibility testing methodologies for DALVANCE® (dalbavancin) (ABSSSI); and the microbiologic activity, pharmacodynamics and efficacy of TEFLARO® (ceftaroline fosamil) for the treatment of acute skin and skin structure infections (ABSSSI).
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
HCP, Inc.(NYSE:HCP), during its Thursday’s current trading session gained 0.31% to $38.69.
HCP (HCP), in recognition of its sustainability achievements, has been named to the Dow Jones Sustainability North America Index for the third successive year, and has achieved constituency for the first time in the Dow Jones Sustainability World Index.
The Dow Jones Sustainability Index Series represents industry leaders that outperform their peers in sustainability metrics based on an analysis of financially material economic, environmental, and social factors. Constituency in the North America Index is awarded to the top 20% of the 600 largest North American companies in the S&P Global Broad Market Index, and constituency in the World Index is awarded to the top 10% of the 2,500 largest companies in the S&P Global Broad Market Index.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry counting sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
